Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.
CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.
Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.
TCG Crossover has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
TCG Crossover's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 15 different industry categories.
Among tracked funding rounds, Immunovant received $550.0M in a Post-IPO Equity round. TCG Crossover's total known invested capital is $14.3B.
TCG Crossover's average investment size is $176.4M across its portfolio of 81 companies.
Recent TCG Crossover portfolio additions include Athira Pharma, Immunovant, Cogent Biosciences, Rapt Therapeutics, Affinia Therapeutics. These companies were founded in 2020 or later.